Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversity Hospital, Toulouse
About this trial
This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.
Eligibility criteria
Qualifiers
Nulliparous women aged 18 years or more
Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor
Singleton pregnancy
Evolutive pregnancy between 9 and 14 weeks of gestation
Disqualifiers
Major fetal abnormality
Regular treatment with aspirin (including antiphospholipid syndrome)
Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia)
Women protected by law.
Trial design
Treatments tested in this trial
- Aspirin
- Placebo
Treatment groups
1,164 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov